IL2 and neoplasm: Some clinical studies investigating the systemic responses to LITs reported that LITs significantly increased the serum levels of IL-2 and IL-12, which both are major mediators for the activation, proliferation, and infiltration of tumor-killing immune cells, indicating the activation of antitumor immunity after LITs [116,147,148,149].